Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketoconazole and Posaconazole in Recurrent High Grade Glioma
NCT03763396Phase 1Not yet recruiting
- Sponsor
- University Health Network
- Start
- Jun 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ketoconazole and posaconazole in high-grade glioma (HGG) (4 arms), sponsored by University Health Network. Primary endpoints: Intratumoral concentrations of KCZ or PCZ and Plasma concentrations of KCZ or PCZ. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
ketoconazoleposaconazole
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT03763396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03763396.